Posted by Michael Wonder on 19 Sep 2023
MHRA approves Moderna’s adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5
15 September 2023 - The vaccine was approved after it was found to meet the MHRA’s standards of safety, quality and effectiveness.
An adapted COVID-19 vaccine from Moderna (Spikevax) that targets the Omicron XBB 1.5 sub-variant, has today been authorised by the MHRA after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
The vaccine has been approved for use in individuals from 6 months of age.
